ZA202106559B - Compositions of matter with activity to remove lipofuscin from retinal cells - Google Patents

Compositions of matter with activity to remove lipofuscin from retinal cells

Info

Publication number
ZA202106559B
ZA202106559B ZA2021/06559A ZA202106559A ZA202106559B ZA 202106559 B ZA202106559 B ZA 202106559B ZA 2021/06559 A ZA2021/06559 A ZA 2021/06559A ZA 202106559 A ZA202106559 A ZA 202106559A ZA 202106559 B ZA202106559 B ZA 202106559B
Authority
ZA
South Africa
Prior art keywords
compositions
activity
matter
retinal cells
lipofuscin
Prior art date
Application number
ZA2021/06559A
Other languages
English (en)
Inventor
M Nociari Marcelo
Rodriguez BOULAN Enrique
Original Assignee
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell filed Critical Univ Cornell
Publication of ZA202106559B publication Critical patent/ZA202106559B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA2021/06559A 2019-03-05 2021-09-07 Compositions of matter with activity to remove lipofuscin from retinal cells ZA202106559B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814028P 2019-03-05 2019-03-05
PCT/US2020/020805 WO2020180872A1 (en) 2019-03-05 2020-03-03 Compositions of matter with activity to remove lipofuscin from retinal cells

Publications (1)

Publication Number Publication Date
ZA202106559B true ZA202106559B (en) 2025-01-29

Family

ID=72337111

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/06559A ZA202106559B (en) 2019-03-05 2021-09-07 Compositions of matter with activity to remove lipofuscin from retinal cells

Country Status (16)

Country Link
US (1) US20220118002A1 (https=)
EP (1) EP3934660A4 (https=)
JP (1) JP7573881B2 (https=)
KR (1) KR20210142651A (https=)
CN (1) CN113747902A (https=)
AU (1) AU2020232266A1 (https=)
BR (1) BR112021017529A2 (https=)
CA (1) CA3132466A1 (https=)
CO (1) CO2021012267A2 (https=)
EA (1) EA202192183A1 (https=)
IL (1) IL286002A (https=)
MX (1) MX2021010650A (https=)
PH (1) PH12021552131A1 (https=)
SG (1) SG11202109541YA (https=)
WO (1) WO2020180872A1 (https=)
ZA (1) ZA202106559B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3205822A1 (en) * 2021-01-22 2022-07-28 Marcelo M. NOCIARI Compositions and methods for the identification of compounds that protect against lipofuscin cytotoxicity
AU2023420130A1 (en) * 2022-12-30 2025-08-14 Cornell University Acid cyclodextrins for the treatment of lipofuscin buildups and ocular diseases
CN116253809B (zh) * 2023-04-19 2024-11-05 广州润虹医药科技股份有限公司 一种去除壳聚糖中内毒素的方法
WO2025147228A1 (en) * 2024-01-02 2025-07-10 Alkeus Pharmaceuticals, Inc. Treatment for asymptomatic stargardt disease patients with gildeuretinol acetate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
US8679511B2 (en) * 2009-10-01 2014-03-25 Duquesne University of the Holy Spririt In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
WO2011072141A1 (en) * 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
US10463687B2 (en) * 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
KR101423631B1 (ko) * 2012-08-17 2014-07-25 주식회사파마킹 에스-알릴엘-시스테인을 유효성분으로 포함하는 안질환 예방 또는 치료용 조성물 및 이를 포함하는 의약제제
WO2014152959A1 (en) * 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
WO2016168772A1 (en) 2015-04-17 2016-10-20 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
GB2556082A (en) 2016-11-18 2018-05-23 Warneford Healthcare Ltd Ophthalmic composition

Also Published As

Publication number Publication date
EP3934660A4 (en) 2022-11-23
JP7573881B2 (ja) 2024-10-28
WO2020180872A1 (en) 2020-09-10
CA3132466A1 (en) 2020-09-10
PH12021552131A1 (en) 2022-08-22
KR20210142651A (ko) 2021-11-25
CN113747902A (zh) 2021-12-03
US20220118002A1 (en) 2022-04-21
EP3934660A1 (en) 2022-01-12
EA202192183A1 (ru) 2022-01-14
IL286002A (en) 2021-10-31
JP2022525007A (ja) 2022-05-11
AU2020232266A1 (en) 2021-09-23
SG11202109541YA (en) 2021-09-29
BR112021017529A2 (pt) 2021-11-09
MX2021010650A (es) 2021-12-10
CO2021012267A2 (es) 2021-10-20

Similar Documents

Publication Publication Date Title
ZA202106559B (en) Compositions of matter with activity to remove lipofuscin from retinal cells
ZA202102488B (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
PH12021552038A1 (en) Compositions and methods to treat bietti crystalline dystrophy
MX2023013435A (es) Composiciones y metodos para expresar otoferlina.
EA201301277A1 (ru) Композиции и способы лечения заболеваний сетчатки
MX2022011546A (es) Composiciones y metodos para el agotamiento de celulas cd137+.
WO2015168149A3 (en) Sensorineural hair cell differentiation
HK1258588A1 (zh) 用於治疗眼科疾病的化合物和制剂
HK1250940A1 (zh) 用於预防上皮细胞的增殖和上皮-间充质转换的组合物和方法
WO2009100438A3 (en) Compounds that enhance atoh-1 expression
MX2016013832A (es) Composiciones y metodos para tratar hemoglobinopatias.
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
MX2025010350A (es) Composiciones y metodos para aumentar la hemoglobina fetal y tratar la anemia de celulas falciformes
MX2023001450A (es) Composiciones y metodos para la inhibicion de la expresion de plp1.
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
WO2019118951A3 (en) Compositions and methods of enhancing the homing and/or engraftment of hematopoietic cells in the central nervous system
JOP20200253A1 (ar) تركيبات وطرق لعلاج الحثل البقعي
EP4420722A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
MX2017007207A (es) Tratamiento de afecciones oculares mediante el uso de celulas progenitoras.
WO2015120436A3 (en) Stat3 phosphorylation during graft-versus-host disease
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
WO2019046341A3 (en) Methods and compositions for treating cone-rod retinal dystrophy
MX2019000050A (es) Tratamiento de la enfermedad vascular retinal mediante el uso de celulas progenitoras.
WO2019227056A3 (en) Methods and compositions involving bucindolol for the treatment of atrial fibrillation